Skip to main content

Table 5 Subgroup analysis between the autologous/MSCs alternative therapy group and the allogeneic/MSCs additional therapy group

From: Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis

Outcomes Autologous/MSCs alternative therapy Allogeneic/MSCs additional therapy Subgroup differences
Number of trials Number of patients RR/WMD 95% CI Number of trials Number of patients RR/WMD 95% CI p value Heterogeneity p value (%)
1-year AR rate 1 103 0.68 0.32, 1.45 3 94 1 0.3, 3.32 0.59 0
1-year graft survival rate 1 103 0.98 0.92, 1.05 2 62 1 0.9, 1.11 0.77 0
DGF rate 1 103 0.98 0.26, 3.71 1 42 0.29 0.07, 1.22 0.22 33.7
1-year infection rate 1 103 0.63 0.42, 0.95 3 94 0.67 0.37, 1.2 0.89 0
Renal graft function postsurgery at 12 months 1 103 1.2 −9.21,11.61 3 94 −2.31 −9.7,5.08 0.59 0
  1. MSCs mesenchymal stromal cells, AR acute rejection, DGF delay graft function, RR risk ratio, WMD weighted mean difference, CI confidence intervals